Last 7 days
-7.5%
Last 30 days
-5.4%
Last 90 days
1.1%
Trailing 12 Months
-23.5%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
A | 40.4B | 6.8B | -13.31% | 3.22% | 32.19 | 5.89 | 8.37% | 3.64% |
ILMN | 35.5B | 4.6B | 5.65% | -27.02% | -8.07 | 7.75 | 1.28% | -677.95% |
MTD | 32.5B | 3.9B | -7.42% | 9.05% | 37.3 | 8.3 | 5.43% | 13.46% |
TECH | 11.5B | 1.1B | -5.60% | -27.97% | 44.06 | 10.31 | 8.77% | 24.82% |
MID-CAP | ||||||||
RGEN | 9.7B | 801.5M | -9.29% | 0.51% | 52.37 | 12.15 | 19.54% | 44.95% |
SMALL-CAP | ||||||||
PACB | 2.0B | 128.3M | -11.70% | -1.09% | -6.37 | 15.61 | -1.69% | -73.40% |
ADPT | 1.2B | 185.3M | -5.41% | -23.53% | -6 | 6.49 | 20.06% | 3.42% |
QTRX | 450.3M | 105.5M | -12.44% | -50.56% | -4.66 | 4.27 | -4.55% | -67.63% |
NSTG | 405.5M | 127.3M | -23.43% | -69.17% | -2.54 | 3.19 | -12.28% | -38.43% |
BNGO | 341.8M | 27.8M | -23.57% | -31.43% | -2.58 | 12.29 | 54.62% | -83.06% |
CDXS | 271.1M | 138.6M | -29.13% | -76.08% | -8.07 | 1.96 | 32.30% | -57.86% |
CDXC | 121.5M | 72.0M | -9.68% | -16.83% | -7.37 | 1.69 | 6.82% | 39.11% |
HBIO | 117.4M | 113.3M | -15.92% | -55.18% | -12.34 | 1.04 | -4.68% | -3204.17% |
CSBR | 54.2M | 54.1M | -0.24% | -45.98% | 502.17 | 1 | 21.80% | -72.38% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 10.3% | 185,308,000 | 168,040,000 | 159,677,000 | 154,522,000 | 154,344,000 |
S&GA Expenses | -3.0% | 95,603,000 | 98,583,000 | 102,019,000 | 100,954,000 | 95,465,000 |
R&D Expenses | -2.4% | 141,756,000 | 145,233,000 | 145,647,000 | 146,410,000 | 142,343,000 |
EBITDA | 1.2% | -190,369,000 | -192,659,000 | - | - | - |
EBITDA Margin | 4.4% | -1.19 | -1.25 | - | - | - |
Earnings Before Taxes | - | -207,298,000 | - | - | - | - |
EBT Margin | 3.2% | -1.30 | -1.34 | - | - | - |
Interest Expenses | 62.3% | 4,238,000 | 2,612,000 | - | - | - |
Net Income | 9.6% | -200,191,000 | -221,496,000 | -232,118,000 | -236,070,000 | -207,279,000 |
Net Income Margin | 18.0% | -1.08 | -1.32 | -1.45 | -1.48 | - |
Free Cahsflow | 13.2% | -200,294,000 | -230,804,000 | -241,026,000 | -247,917,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -3.1% | 857 | 884 | 807 | 858 | 923 |
Current Assets | -0.4% | 562 | 564 | 439 | 419 | 403 |
Cash Equivalents | -58.6% | 90.00 | 218 | 76.00 | 115 | 139 |
Inventory | -16.7% | 14.00 | 17.00 | 19.00 | 21.00 | 19.00 |
Net PPE | -3.7% | 83.00 | 87.00 | 87.00 | 86.00 | 85.00 |
Goodwill | 0% | 119 | 119 | 119 | 119 | 119 |
Liabilities | -1.0% | 393 | 396 | 288 | 305 | 319 |
Current Liabilities | 5.5% | 110 | 104 | 111 | 115 | 114 |
Shareholder's Equity | -4.9% | 464 | 488 | 518 | 553 | 604 |
Retained Earnings | -4.6% | -919 | -878 | -833 | -781 | -718 |
Additional Paid-In Capital | 1.1% | 1,387 | 1,373 | 1,358 | 1,340 | 1,324 |
Accumulated Depreciation | - | 36.00 | - | - | - | - |
Shares Outstanding | 0.1% | 143 | 143 | 143 | 142 | 141 |
Minority Interest | -157.7% | -0.07 | -0.03 | 0.00 | 0.00 | 0.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 11.5% | -183 | -207 | -208 | -198 | -192 |
Share Based Compensation | 4.6% | 55.00 | 53.00 | 51.00 | 48.00 | 43.00 |
Cashflow From Investing | -98.3% | 3.00 | 168 | 88.00 | 125 | 181 |
Cashflow From Financing | -2.4% | 132 | 136 | 13.00 | 15.00 | 27.00 |
98.5%
92.3%
90.8%
Y-axis is the maximum loss one would have experienced if Adaptive BioTech was unfortunately bought at previous high price.
-25.3%
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -0.04 | 8,407 | 121,407 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -5.96 | 11,000 | 1,271,000 | 0.01% |
2023-03-03 | TIAA, FSB | reduced | -14.83 | -16,471 | 175,529 | -% |
2023-02-28 | Voya Investment Management LLC | unchanged | - | 22,444 | 329,444 | -% |
2023-02-22 | CVA Family Office, LLC | unchanged | - | 247 | 3,247 | -% |
2023-02-21 | MACQUARIE GROUP LTD | reduced | -24.51 | -111,000 | 442,000 | -% |
2023-02-16 | HARBOUR INVESTMENTS, INC. | unchanged | - | -183 | 817 | -% |
2023-02-15 | CAPTRUST FINANCIAL ADVISORS | sold off | -100 | -88,000 | - | -% |
2023-02-15 | Cerity Partners LLC | reduced | -0.2 | 80,144 | 1,209,140 | 0.01% |
2023-02-15 | LAZARD ASSET MANAGEMENT LLC | reduced | -46.28 | -1,148,000 | 1,563,000 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 13, 2023 | blackrock inc. | 8.7% | 12,374,197 | SC 13G | |
Feb 09, 2023 | vanguard group inc | 8.25% | 11,794,168 | SC 13G/A | |
Sep 12, 2022 | price t rowe associates inc /md/ | 2.9% | 4,081,518 | SC 13G/A | |
Feb 14, 2022 | matrix capital management company, lp | 8.20% | 11,572,590 | SC 13G/A | |
Feb 14, 2022 | viking global investors lp | 21.3% | 29,993,708 | SC 13G/A | |
Feb 10, 2022 | price t rowe associates inc /md/ | 10.0% | 14,240,614 | SC 13G/A | |
Feb 10, 2022 | price t rowe associates inc /md/ | 9.4% | 13,286,713 | SC 13G | |
Feb 09, 2022 | vanguard group inc | 7.82% | 11,031,288 | SC 13G/A | |
Feb 16, 2021 | viking global investors lp | 21.9% | 29,993,708 | SC 13G/A | |
Feb 16, 2021 | matrix capital management company, lp | 9.59% | 13,115,090 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 0.90 -89.29% | 1.11 -86.79% | 1.71 -79.64% | 2.82 -66.43% | 4.33 -48.45% |
Current Inflation | 0.89 -89.40% | 1.07 -87.26% | 1.60 -80.95% | 2.56 -69.52% | 3.85 -54.17% |
Very High Inflation | 0.87 -89.64% | 1.03 -87.74% | 1.47 -82.50% | 2.25 -73.21% | 3.30 -60.71% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading | |
Mar 08, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-07 | Taylor Stacy L | sold | -115,128 | 8.6 | -13,387 | svp and general counsel |
2023-03-07 | ADAMS R MARK | sold | -147,533 | 8.6 | -17,155 | chief operating officer |
2023-03-07 | SOOD NITIN | sold | -84,391 | 8.6 | -9,813 | chief commercial officer, mrd |
2023-03-06 | Taylor Stacy L | sold | -47,057 | 8.57 | -5,491 | svp and general counsel |
2023-03-06 | Conroy Kevin T | acquired | - | - | 14,775 | - |
2023-03-06 | LO FRANCIS | sold | -58,413 | 8.57 | -6,816 | chief people officer |
2023-03-06 | ADAMS R MARK | acquired | - | - | 88,652 | chief operating officer |
2023-03-06 | ROBINS HARLAN S | acquired | - | - | 354,610 | chief scientific officer |
2023-03-06 | HERSHBERG ROBERT | acquired | - | - | 14,775 | - |
2023-03-06 | LO FRANCIS | acquired | - | - | 85,697 | chief people officer |
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue | |||
Revenue | $ 185,308 | $ 154,344 | $ 98,382 |
Operating expenses | |||
Cost of revenue | 57,909 | 49,301 | 22,530 |
Research and development | 141,756 | 142,343 | 116,072 |
Sales and marketing | 95,603 | 95,465 | 61,358 |
General and administrative | 88,527 | 74,502 | 49,536 |
Amortization of intangible assets | 1,699 | 1,699 | 1,703 |
Total operating expenses | 385,494 | 363,310 | 251,199 |
Loss from operations | (200,186) | (208,966) | (152,817) |
Interest and other income, net | 4,056 | 1,668 | 6,590 |
Interest expense | (4,238) | ||
Net loss | (200,368) | (207,298) | (146,227) |
Add: Net loss attributable to noncontrolling interest | 177 | 19 | |
Net loss attributable to Adaptive Biotechnologies Corporation | $ (200,191) | $ (207,279) | $ (146,227) |
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic | $ (1.40) | $ (1.48) | $ (1.11) |
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic | 142,515,917 | 140,354,915 | 131,216,468 |
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted | $ (1.40) | $ (1.48) | $ (1.11) |
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted | 142,515,917 | 140,354,915 | 131,216,468 |
Consolidated Balance Sheets - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 90,030,000 | $ 139,065,000 |
Short-term marketable securities (amortized cost of $412,282 and $214,115, respectively) | 408,166,000 | 213,996,000 |
Accounts receivable, net | 40,057,000 | 17,409,000 |
Inventory | 14,453,000 | 19,263,000 |
Prepaid expenses and other current assets | 9,440,000 | 13,015,000 |
Total current assets | 562,146,000 | 402,748,000 |
Long-term assets | ||
Property and equipment, net | 83,447,000 | 85,262,000 |
Operating lease right-of-use assets | 80,763,000 | 87,678,000 |
Long-term marketable securities (amortized cost of $218,163) | 217,145,000 | |
Restricted cash | 2,398,000 | 2,138,000 |
Intangible assets, net | 6,827,000 | 8,526,000 |
Goodwill | 118,972,000 | 118,972,000 |
Other assets | 2,064,000 | 875,000 |
Total assets | 856,617,000 | 923,344,000 |
Current liabilities | ||
Accounts payable | 8,084,000 | 3,307,000 |
Accrued liabilities | 12,424,000 | 9,343,000 |
Accrued compensation and benefits | 15,935,000 | 15,642,000 |
Current portion of operating lease liabilities | 9,230,000 | 5,055,000 |
Current deferred revenue | 64,115,000 | 80,460,000 |
Total current liabilities | 109,788,000 | 113,807,000 |
Long-term liabilities | ||
Operating lease liabilities, less current portion | 98,772,000 | 106,685,000 |
Deferred revenue, less current portion | 58,599,000 | 98,750,000 |
Revenue interest liability, net | 125,360,000 | |
Total liabilities | 392,519,000 | 319,242,000 |
Commitments and contingencies (Note 12) | ||
Shareholders’ equity | ||
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2022 and 2021; no shares issued and outstanding at December 31, 2022 and 2021 | ||
Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2022 and 2021; 143,105,002 and 141,393,865 shares issued and outstanding at December 31, 2022 and 2021, respectively | 14,000 | 14,000 |
Additional paid-in capital | 1,387,349,000 | 1,324,006,000 |
Accumulated other comprehensive loss | (4,116,000) | (1,137,000) |
Accumulated deficit | (919,082,000) | (718,891,000) |
Total Adaptive Biotechnologies Corporation shareholders’ equity | 464,165,000 | 603,992,000 |
Noncontrolling interest | (67,000) | 110,000 |
Total shareholders’ equity | 464,098,000 | 604,102,000 |
Total liabilities and shareholders’ equity | $ 856,617,000 | $ 923,344,000 |